Mexican Good Manufacturing Practices for Medicines
Mexico’s official standard for GMP of medicines for human use (NORMA Oficial Mexicana NOM-059-SSA1-2015, “Buenas prácticas de fabricación de medicamentos”), published in the Diario Oficial de la Federación on 5 February 2016 and in force 180 natural days later. It sets the minimum requirements for manufacturing human-use medicines marketed in Mexico or used for research, across 21 sections that run from the quality management system and quality risk management through personnel, facilities, qualification and validation, manufacturing systems, QC laboratory, batch release, market withdrawal, outsourced activities, waste disposal, and good storage and distribution practice.
What this does not cover
stated in the document's own scope- Covers GMP for finished medicines for human use; other supply classes carry their own Normas Oficiales Mexicanas.
- Sets manufacturing GMP, not the marketing-authorisation (registro sanitario) pathway, which COFEPRIS governs separately.
- Establishes the mandatory GMP requirements, not the internal test methods, which come from the applicable pharmacopoeia (Farmacopea de los Estados Unidos Mexicanos).
Always verify against the current published text before relying on it for a submission or inspection.
Overview
NOM-059-SSA1-2015 is Mexico’s official standard for the Good Manufacturing Practices of medicines for human use — its full title is “Buenas prácticas de fabricación de medicamentos.” It is the fundamental GMP requirement COFEPRIS enforces, and it runs across the pharmaceutical quality system, personnel, documentation, facilities and equipment, production, quality control, storage and distribution. As an official Mexican standard (Norma Oficial Mexicana), it states mandatory requirements a manufacturer must meet, written in the numbered-clause structure characteristic of the NOM system rather than as advisory best practice.
Scope & applicability
Wider than its title suggests. Section 1.2 makes the norm binding not only on manufacturers but on importers, quality control laboratories, and packaging, storage and distribution warehouses — “fabricación y/o importación”, named together. Two normative appendices carry the detail that is most often cited: Appendix A classifies manufacturing areas with maximum permitted particle counts, and Appendix B governs the Annual Product Review. Compliance is supervised by the Secretaría de Salud and by state governments within their competences.
Legal basis & how it acquires force
The standard was published in the Diario Oficial de la Federación on 5 February 2016 and takes its authority from Mexico’s General Health Law and the regulations on health supplies. A Norma Oficial Mexicana is a mandatory technical regulation, so NOM-059 is legally binding for the Mexican market, not guidance. COFEPRIS (Comisión Federal para la Protección contra Riesgos Sanitarios) is the sanitary-risk authority that verifies compliance, and meeting NOM-059 is a condition of the manufacturing authorisation a site needs to supply medicines in Mexico.
Document structure
| Part | Covers |
|---|---|
| Quality management | The pharmaceutical quality system and quality-unit responsibilities |
| Personnel and hygiene | Organisation, training, and personnel hygiene requirements |
| Facilities and equipment | Design, qualification, and maintenance of premises and equipment |
| Documentation | The documentation system, master and batch records, and data controls |
| Production and controls | Manufacturing operations, in-process control, and the quality-control laboratory |
| Validation, storage, and distribution | Process and cleaning validation, storage conditions, and distribution controls |
Quick reference · Who NOM-059 binds
Section 1.2, campo de aplicación. The norm is commonly read as a manufacturing rule; its own scope clause is wider, and importers are the most frequently missed.
- Manufacturers — establishments manufacturing human-use medicines sold in Mexico or used for research
- Importers — named explicitly alongside manufacturers — “fabricación y/o importación”
- Quality control laboratories — laboratorios de control de calidad, in scope in their own right
- Packaging warehouses — almacenes de acondicionamiento
- Storage and distribution warehouses — almacenes de depósito y distribución, with §16 setting good storage and distribution practice
Compliance is overseen by the Secretaría de Salud and by state governments within their respective competences (§19), so enforcement is not COFEPRIS-only.
Source: NOM-059-SSA1-2015 §1.2 and §19, Diario Oficial de la Federación, 5 February 2016. Verify against the current text before relying on it for a submission.
Key requirements
- Operate a quality management system (§5) and quality risk management (§6) as the norm’s foundation, ahead of the technical chapters
- Meet the facility and equipment requirements of §8 and the area classification in normative Appendix A
- Qualify and validate under §9, and maintain the supporting documentation
- Run an independent quality control laboratory (§11) and a defined finished-product release step (§12)
- Maintain a market-withdrawal procedure (§13) and control outsourced activities (§14)
- Apply good storage and distribution practice (§16) — the norm reaches into the warehouse, not only the plant
- Perform the Annual Product Review required by normative Appendix B
Implementation tips
- Check whether you are in scope as an importer or a warehouse, not only as a manufacturer — §1.2 names all of them and importers are the most commonly missed
- Read Appendices A and B as normative, not informative: area classification and the Annual Product Review are requirements, not guidance
- Track the 2024 amendment: COFEPRIS published a PROYECTO DE MODIFICACIÓN of several points of NOM-059 for public comment, so parts of the text you are reading are under revision
- Expect oversight from state health authorities as well as COFEPRIS, per §19
Revision notes
Published in the DOF on 5 February 2016 and entering into force 180 natural days afterwards, NOM-059-SSA1-2015 cancelled NOM-059-SSA1-2013, published in the DOF on 22 July 2013 (Transitorio Único). It remains in force: on 6 September 2024 COFEPRIS published in the DOF a PROYECTO DE MODIFICACIÓN DE DIVERSOS PUNTOS of NOM-059-SSA1-2015, opening a 60-natural-day comment period through the Comité Consultivo Nacional de Normalización de Regulación y Fomento Sanitario. That is a draft amendment to specific points, not a replacement norm — the 2015 text stands until a modification is published as final.
Where this control fails
live FDA enforcementLive FDA recalls SPEQ maps to this standard’s topics — a SPEQ interpretation, not an FDA classification.
International alignment
COFEPRIS is a PIC/S participating authority, and NOM-059 is broadly consistent with the PIC/S GMP Guide and WHO GMP, which brings Mexican GMP into line with the international reference that mirrors EU GMP. The alignment supports comparability of inspection outcomes and international recognition, while the binding requirement in Mexico remains the NOM itself as enforced by COFEPRIS.
NOM-059-SSA1-2015: frequently asked questions
Quick answers to common questions about NOM-059-SSA1-2015.
When was NOM-059-SSA1-2015 published?
It was published in the Diario Oficial de la Federación on 5 February 2016. The “2015” in its code is the standard’s designation year; the DOF publication date is when it took legal effect.
Is NOM-059 mandatory?
Yes. A Norma Oficial Mexicana is a mandatory technical regulation under Mexico’s General Health Law, so NOM-059 is legally binding and COFEPRIS verifies compliance — it is not advisory guidance.
Is Mexico’s GMP aligned with international standards?
Broadly, yes. COFEPRIS is a PIC/S participating authority and NOM-059 is consistent with the PIC/S GMP Guide and WHO GMP, which mirror EU GMP.
This standard in practice
Recall domain is a SPEQ mapping of this standard’s topics, not an FDA classification.